IMWG Revises International Staging System for Multiple Myeloma

Share this content:
The revised ISS should be used in future clinical studies to effectively stratify for newly diagnosed multiple myeloma by relative risk for survival.
The revised ISS should be used in future clinical studies to effectively stratify for newly diagnosed multiple myeloma by relative risk for survival.

The revised International Staging System (ISS) is a new risk stratification algorithm with improved prognostic power compared with the individual ISS, chromosomal abnormalities, and serum lactate dehydrogenase parameters in patients with newly diagnosed multiple myeloma, according to a report from the International Myeloma Working Group (IMWG) published online ahead of print in the Journal of Clinical Oncology.1

The American Cancer Society estimates that nearly 27,000 Americans will be diagnosed with multiple myeloma in 2015 and approximately 11,240 patients will die from the disease.2

Previously, the ISS, which was published in 2005, was a simple risk stratification system that was only based on serum β2-microglobulin level and serum albumin level, but chromosomal abnormalities and serum lactate deydrogenase level are key elements to characterize biologic features of multiple myeloma.1

“The revision was required to integrate both ISS, chromosomal abnormalities, and LDH,” Antonio Palumbo, MD, lead author and Chief of the Myeloma Unit at the University of Torino in Italy said in an interview with Cancer Therapy Advisor.

RELATED: FDA Approves Kyprolis as Second-Line Treatment for Multiple Myeloma

For the study, researchers from the IMWG analyzed clinical and laboratory data from 4,445 patients with newly diagnosed multiple myeloma who participated in 11 international trials. Of those, ISS, chromosomal abnormalities, and serum lactate dehydrogenase data were available in 3,060 patients.1

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters